GLOBAL BLOOD THERAPEUTICS Stock News

A medical expert, Dr David Ajibade, says children below the age of 12 with sickle cell disorder, can live an almost normal life, if proper care

New company, co-founded with UCSF scientists and being incubated in San Francisco, will apply computational sciences and machine learning to accelerate drug discovery in Parkinson’s disease, ALS, es

As the world marked 2020 world sickle cell disorder, SCD, day, a coalition of NGOs has decried the alarming rate of cases in the country.

Both of these biotech companies recently released encouraging data from clinical trials.

Sickle cell disease can lead to a lot of complication, including stroke, acute chest syndrome, pulmonary hypertension, organ damage, blindness, leg ulcers, among others.

Find and download new songs, or grab old favorites

La société prévoit de demander une autorisation de mise sur le marché complète pour Oxbryta pour le traitement de l'anémie hémolytique dans la...

SOUTH SAN FRANCISCO, Calif., June 25, 2020 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that five U.S. nonprofit organizations serving the sickle cell.

Global Blood (GBT) plans to seek approval for Oxbryta tablets to treat hemolytic anemia in SCD patients aged 12 years and older in Europe.

William Blair analyst Raju Prasad maintained a Buy rating on Global Blood Therapeutics (GBT – Research Report) today. The company’s

An oral, once daily therapy, Oxbryta directly inhibits hemoglobin polymerization, the root cause of the sickling and destruction of red blood cells in SCD. The sickling process causes hemolytic anemi

Shares in Editas Medicine (EDIT) are falling 6% in Wednesday’s pre-market trading after the company announced a price of $31.25 per share for its

Sefiat (not real name), became rebellious to her parents because she could no longer bear the pain she was suffering. She began to question why she was treated differently from  her other siblings;�

Experimental genetic treatments could hold the key to a better quality of life for patients and long-term returns for CRISPR stock.

Deutsche Bank AG lessened its stake in Global Blood Therapeutics Inc (NASDAQ:GBT) by 4.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Co